Drug Type Small molecule drug |
Synonyms Suplatast tosilate (JAN/INN), Suplatast tosylate, IPD 1151T + [8] |
Target |
Mechanism IL-4Rα inhibitors(Interleukin-4 receptor subunit alpha inhibitors), IL-5Rα inhibitors(Interleukin-5 receptor subunit alpha inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (20 Jan 1995), |
Regulation- |
Molecular FormulaC23H33NO7S2 |
InChIKeyRYVJQEZJUFRANT-UHFFFAOYSA-N |
CAS Registry94055-76-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01423 | Suplatast Tosilate | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypersensitivity | CN | 22 Nov 2012 | |
Asthma | JP | 20 Jan 1995 | |
Dermatitis, Atopic | JP | 20 Jan 1995 | |
Rhinitis, Allergic | JP | 20 Jan 1995 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cystitis, Interstitial | Phase 3 | JP | - | - |
Chronic cough | Phase 2 | IN | Melius Pharma ABStartup | 01 Apr 2024 |
Idiopathic Pulmonary Fibrosis | Phase 2 | IN | Melius Pharma ABStartup | 01 Apr 2024 |
Prostatitis | Phase 2 | JP | - |